Global Allergic Conjunctivitis Market Size study, By Drug Class (Antihistamines & Mast Cell Stabilizers, Corticosteroids), By Disease Type (Seasonal Allergic Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC)), By Distribution Channel (Hospital

Global Allergic Conjunctivitis Market Size study, By Drug Class (Antihistamines & Mast Cell Stabilizers, Corticosteroids), By Disease Type (Seasonal Allergic Conjunctivitis (SAC), Perennial Allergic Conjunctivitis (PAC)), By Distribution Channel (Hospital Pharmacies, Drug stores & Retail Pharmacies, Online providers), and Regional Forecasts 2022-2028

Global Allergic Conjunctivitis Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028.

Allergic Conjunctivitis can be defined as an inflammation of the lining of the eye called conjunctiva due to allergens. In Allergic Conjunctivitis, conjunctiva becomes swollen or inflamed owing to reaction caused by pollen, dust mites, pet dander, mold, and allergy-causing substances. The other symptoms of allergic conjunctivitis include sharp itching of eyes and urge to rub eyes, red eyes, watery or white stringy mucus discharge and Swollen eyelids among others. The rising incidences of allergic conjunctivitis worldwide, increasing prevalence of allergens as well as recent approvals from regulating authorities are factors that are accelerating the global market demand. For instance, as per The National Center for Biotechnology Information estimates – as of 2022, Allergic conjunctivitis affected around 40 percent of the US population, but only a small proportion of affected individuals seek medical treatment. Further, as per the Asthma and Allergy Foundation of America (AAFA) – allergies are sixth leading cause of chronic illness in the U.S. and each year around 50 million U.S. citizen experience various types of allergies. Moreover, the market has witnessed several product approvals, this factor would also influence the growth of Global Allergic Conjunctivitis Market during the forecast period. For instance, in March 2019, Alembic Pharmaceuticals received approval from US FDA for its drug Azelastine Hydrochloride Ophthalmic Solution utilized for treatment of allergic conjunctivitis. Moreover, in October 2021, the US FDA approved Massachusetts, USA based biopharmaceutical company Ocular Therapeutix Inc.’s intracanalicular insert drug named Dextenza. This new formulation intended for treatment of ocular itching associated with allergic conjunctivitis. Also, growing advancements in ocular allergy therapeutics and rising expansion of healthcare services in emerging markets are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, a lack of awareness towards allergic conjunctivitis treatment impedes the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Allergic Conjunctivitis Mmarket study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing incidences of allergic conjunctivitis and presence of leading market players in the region. Whereas, Asia Pacific is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as the thriving growth of healthcare sector and rising per capita healthcare spending in the region, would create lucrative growth prospects for the global Allergic Conjunctivitis Mmarket across the Asia Pacific region.

Major market players included in this report are:
AbbVie Inc.
Ajanta Pharma Limited
Akron Operating Company LLC
Alembic Pharmaceuticals Ltd.
Bausch Health Companies Inc.
Cipla Ltd
Grevis Pharmaceutical Private Limited
Indoco Remedies Ltd.
Jabs Biotech Pvt. Ltd.
JAWA Pharmaceuticals Pvt. Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class
Antihistamines & Mast Cell Stabilizers
Corticosteroids
By Disease Type
Seasonal Allergic Conjunctivitis (SAC)
Perennial Allergic Conjunctivitis (PAC)
By Distribution Channel
Hospital Pharmacies
Drug stores & Retail Pharmacies
Online providers
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Allergic Conjunctivitis Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

AbbVie Inc.
Ajanta Pharma Limited
Akron Operating Company LLC
Alembic Pharmaceuticals Ltd.
Bausch Health Companies Inc.
Cipla Ltd
Grevis Pharmaceutical Private Limited
Indoco Remedies Ltd.
Jabs Biotech Pvt. Ltd.
JAWA Pharmaceuticals Pvt. Ltd.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.